neoadjuvant hormonal therapy
Recently Published Documents


TOTAL DOCUMENTS

149
(FIVE YEARS 2)

H-INDEX

20
(FIVE YEARS 0)

Author(s):  
Gaëtan Devos ◽  
Wout Devlies ◽  
Gert De Meerleer ◽  
Marcella Baldewijns ◽  
Thomas Gevaert ◽  
...  


Author(s):  
Kazuhiro Matsumoto ◽  
Naoya Niwa ◽  
Takeo Kosaka ◽  
Toshikazu Takeda ◽  
Yota Yasumizu ◽  
...  


2020 ◽  
Vol 38 (10) ◽  
pp. 559-564 ◽  
Author(s):  
Nobuaki Sato ◽  
Masaki Shiota ◽  
Ken-ichiro Shiga ◽  
Eiji Kashiwagi ◽  
Ario Takeuchi ◽  
...  


2020 ◽  
Vol 40 (10) ◽  
pp. 5567-5575
Author(s):  
TSUTOMU YUNO ◽  
YASUYOSHI MIYATA ◽  
TOMOHIRO MATSUO ◽  
YUTA MUKAE ◽  
ASATO OTSUBO ◽  
...  


2019 ◽  
Vol 105 (1) ◽  
pp. E6-E7
Author(s):  
A.M. Sexton ◽  
S. Samuels ◽  
S. Dooley ◽  
W. Zhao ◽  
I.M. Reis ◽  
...  


2019 ◽  
Vol 106 (2) ◽  
pp. 133-138
Author(s):  
Lijiang Sun ◽  
Ting Xu ◽  
Xiaoliang Yuan ◽  
Feng Liu ◽  
Fengju Guan ◽  
...  

Objective: This study aimed to investigate the relationship between obesity and pathologic features and biochemical recurrence in patients with prostate cancer (PCa) undergoing radical prostatectomy (RP) after neoadjuvant hormonal therapy (NHT). Methods: A total of 422 consecutive patients with clinically localized PCa who received NHT before RP were retrospectively analyzed. Unconditional multiple logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) regarding probability. A receiver operating characteristic (ROC) curve was used to assess the efficacy of the predictive variables. Castration resistance free survival curves were obtained using the Kaplan-Meier method, and were compared using the log-rank test. Results: Being overweight was associated with an increased risk of positive margins (OR 2.281; 95% CI 1.292–4.028) after adjusting for potential confounders. The area under the ROC curve for overweight patients was larger than that for patients in the normal weight range. There was no significant difference between the overweight and normal weight groups regarding castration resistance free survival. Conclusions: Being overweight was associated with positive margins in patients with PCa undergoing RP after NHT.



The Prostate ◽  
2019 ◽  
Vol 79 (7) ◽  
pp. 709-719 ◽  
Author(s):  
Xueli Wang ◽  
Mei Qi ◽  
Jing Zhang ◽  
Xiubin Sun ◽  
Hongwei Guo ◽  
...  


2019 ◽  
Vol 12 (4) ◽  
pp. 109
Author(s):  
Ramadhan Karsono ◽  
Denni Joko Purwanto ◽  
Samuel J. Haryono ◽  
Bambang Karsono ◽  
Lenny Sari ◽  
...  

Background: There are no data of efficacy comparison between primary systemic therapy in stage 3B and 4 breast cancer patients in Indonesia. This study compared long term outcomes of breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)Methods: This was a cohort study conducted from 2011 to 2017. A total of 122 patients with stage 3B and 4 breast cancer received NAHT (n = 62) or NACT (n = 60) within a 6 cycles for NACT and 6 months for NAHT were included. Patients were excluded if they had a mastectomy before treatment, were pregnant, had been given hormonal therapy or chemotherapy before, had a contra-indication of chemotherapy, had a contra-indication of salpingo-oophorectomy bilateral for premenopausal patients, and declined to enter this study. The primary outcome of this study was overall survival. The outcomes were analysed using Kaplan-Meier for survival analysis and cox proportional hazard regression to estimate the hazard ratio.Results: There was a statistically significant difference in overall survival (p = 0.038). Median overall survival for NAHT patients was 1265 days and for NACT patients was 654 days. The hazard ratio showed NACT patients had a higher risk than NAHT patients (1.7 95% CI 1.03 – 2.9). Pathological complete response rate was higher in the NACT group than in the NAHT group (3.3% vs. 0%).Conclusions: Neoadjuvant hormonal therapy was superior to neoadjuvant chemotherapy in term of overall survival.



Sign in / Sign up

Export Citation Format

Share Document